Pancreas News and Research

RSS

The pancreas is a gland organ in the digestive and endocrine system of vertebrates. It is both an endocrine gland producing several important hormones, including insulin, glucagon, and somatostatin, as well as an exocrine gland, secreting pancreatic juice containing digestive enzymes that pass to the small intestine. These enzymes help in the further breakdown of the carbohydrates, protein, and fat in the chyme.

New registry data shows semaglutide does not cause pancreatic cancer

New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) shows no link between semaglutide use and pancreatic cancer using nationwide registry data from Denmark, Sweden and Norway.

29 Sep 2026

Five-session SBRT preserves quality of life before pancreatic cancer surgery

Patients preparing for pancreatic cancer surgery maintained better physical function and experienced less fatigue with five treatments of stereotactic body radiation therapy (SBRT) than with 28 treatments of conventional radiation therapy given with chemotherapy, according to a randomized phase 2 clinical trial.

28 Sep 2026

National study benchmarks pancreatic cancer surgery outcomes across China

Pancreatic cancer is among the most aggressive malignancies, and in China it accounts for a substantial and rising share of cancer deaths.

25 Sep 2026

As GLP-1 drugs become more complex, their effects on the heart are getting harder to predict

A brief report reviews emerging GLP-1 receptor co-agonists that also target GIPR, GCGR, and other receptors, examining their metabolic benefits alongside known and predicted cardiac effects. The authors highlight substantial species differences, warning that mouse heart studies may fail to predict responses in human cardiac tissue and that many proposed cardiac effects still require direct testing.

24 Sep 2026

GLP-1 drugs may influence chronic pain through gut-brain and immune pathways

Researchers reviewed evidence linking GLP-1 and GLP-1 receptor agonists to chronic pain modulation through gut microbial, neuroimmune, vagal, and metabolic pathways, with the strongest clinical evidence currently involving knee osteoarthritis and idiopathic intracranial hypertension headache. Much of the proposed biology remains supported by preclinical research, and human studies have yet to establish that GLP-1RA-induced changes in the gut microbiome directly cause pain relief.

24 Sep 2026

Early treatment may improve outcomes in Shwachman-Diamond syndrome

More than 90% of children born with the rare bone marrow condition called Shwachman-Diamond Syndrome (SDS) survive beyond age 20. But fewer than 30% live beyond age 50.

23 Sep 2026

Y chromosome loss creates hidden cancer vulnerability in men

A study initiated by a University of Arizona Cancer Center physician-scientist Dr. Dan Theodorescu revealed that the loss of the Y chromosome in men's body tissue could pave the way for cancer to develop in that tissue.

18 Sep 2026

Novel blood test could detect pancreatic cancer at its earliest stages

Researchers at City of Hope, one of the largest and most advanced cancer research and treatment organizations in the country, led the development of a new, investigational blood test that could detect pancreatic cancer at its earliest stages, when the disease is more treatable and potentially curable.

16 Sep 2026

Biological mechanisms validate structured exercise as therapeutic in oncology care

Structured exercise may help people with cancer live longer and have more time free of disease, finds a synthesis of the available evidence, published online in the British Journal of Sports Medicine.

16 Sep 2026

Advanced AI cell models redefine modern cell biology research

Researchers at Stanford Medicine have developed two new artificial intelligence models of the biological cell.

15 Sep 2026

Innovative device improves real-time monitoring of donated lungs

More than three-quarters of donated lungs offered for transplantation are not used, according to the UK's National Institute for Health and Care Excellence, contributing to a chronic shortage of organs for patients with end-stage lung disease.

10 Sep 2026

Rentosertib shifts multiple proteomic aging clocks toward younger age profiles in IPF trial

Researchers applied six proteomic aging clocks to serum samples from a phase 2a trial of rentosertib in people with idiopathic pulmonary fibrosis and found treatment-associated shifts toward younger predicted biological-age profiles, particularly with the 30 mg twice-daily regimen. Additional proteomic analyses linked treatment to changes in senescence, metabolism, growth-factor signaling, and fibrosis-related pathways, although the study could not determine whether these effects reflected genuine geroprotection rather than disease modification.

10 Sep 2026

JMIR Publications: Emerging health tech trends

JMIR Publications released three feature News and Perspectives articles this week, covering an emerging application of drone delivery, the implications of AI tools used in early education, the nascent field of cancer neurotech, and the future of consumer wearable devices.

4 Sep 2026

FDA approves daraxonrasib for metastatic pancreatic cancer following landmark clinical trial led by Dana-Farber

The U.S. Food and Drug Administration (FDA) has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.

From Dana-Farber Cancer Institute, Inc. 29 Aug 2026

Newly developed radiotheranostic pair identifies and treats renal tumors

A newly developed radiotheranostic pair, 68Ga/177Lu-NYM096, can identify tumors and effectively deliver targeted radiotherapy to patients with metastatic clear cell renal cell carcinoma (ccRCC).

28 Aug 2026

Ketogenic diet excels at reversing prediabetes and fatty liver

There is no shortage of popular diets to try, and they can generally produce weight loss if followed to the letter. But are all diet plans created equal in terms of reducing the cardiometabolic risks that come with obesity, such as Type 2 diabetes and liver disease?

27 Aug 2026